[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"left-ventricular-fibrosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:left-ventricular-fibrosis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100600918","primary-ancillary-substudy-100600918",false,"NCT07103733","PRIMARY Ancillary Substudy","Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY) Ancillary Substudy","Inclusion Criteria:\n\n* Patients who meet all eligibility criteria and are randomized in the parent PRIMARY trial.\n* For the ancillary biospecimen study, patients who are randomized to MVr in the parent trial.\n\nExclusion Criteria:\n\n* Severe claustrophobia not controlled with sedation.\n* Prior adverse reaction to gadolinium administration.\n* Patients with an implantable subcutaneous cardioverter defibrillator and\u002For cardiac resynchronization therapy device with defibrillator may be excluded as they typically produce substantial artifacts on cardiac MRI making assessment very challenging.\n* Known allergic reaction to adhesives or hydrogels or with family history of adhesive skin allergies (for patients undergoing rhythm monitoring).","ALL","60 Years",{"count":19,"type":20},250,"ESTIMATED","INTERVENTIONAL",[23],"NA","The PRIMARY trial (NCT05051033), which compares mitral valve repair (MVr) to transcatheter-edge-to-edge-repair (TEER), offers a platform for conducting mechanistic studies to develop early insights into the pathophysiological processes by which mitral valve prolapse (MVP) can impact left ventricular (LV) myocardial structure and function, and, thereby, predispose to arrhythmias and sudden death. Such insights are key to identifying interventions to reduce the long-term sequelae of heart failure (HF) and arrhythmias, as well as delineate optimal therapeutic approaches for different patient sub-groups.",[26,27,28],"Mitral Valve Prolapse","Left Ventricular Fibrosis","Ventricular Arrhythmias",[30,31,32,33,34],"Mitral valve repair (MVr)","Transcatheter-edge-to-edge-repair (TEER)","Cardiac magnetic resonance imaging (CMR)","ZioPatch monitoring","Heart biopsy","RECRUITING","2025-08-14",{"date":38,"type":39},"2025-08-19","ACTUAL",{"date":41,"type":39},"2023-10-16",{"date":43,"type":20},"2027-06-30",{"name":45,"class":46},"Annetine Gelijns","OTHER",25]